{
    "clinical_study": {
        "@rank": "68799", 
        "acronym": "SEMITEP", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "PET-TDM\ncarboplatine: Dose (mg) = AUC x (GFR + 25)\nGFR : glom\u00e9rulaire filtration (ml/min)\nAUC : area under curve (mg/ml x min)"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "PET-TDM\nETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)\ncarboplatine: Dose (mg) = AUC x (GFR + 25)\nGFR : glom\u00e9rulaire filtration (ml/min)\nAUC : area under curve (mg/ml x min)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the ration of patients getting an lighten\n      therapeutic strategy after 18F-fluoro-d\u00e9soxyglucose positron emission tomography (PET-TDM)\n      in grade I (cohort 1) or metastatic (cohort 2) seminoma"
        }, 
        "brief_title": "Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma", 
        "completion_date": {
            "#text": "June 2026", 
            "@type": "Anticipated"
        }, 
        "condition": "Seminoma", 
        "condition_browse": {
            "mesh_term": "Seminoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria shared:\n\n          -  Histologically proved seminoma after orchiectomy\n\n          -  Primary testicular or retroperitoneal\n\n          -  Normal alpha-fetoprotein before and after orchiectomy\n\n          -  No prior treatment with radiotherapy or chemotherapy\n\n          -  Age >= 18 years\n\n          -  ECOG 0 to 2\n\n          -  PNN >= 1500, platelets >= 100 000, bilirubin <= the upper limit nromale\n\n          -  ASAT (SGOT) and ALAT (SGPT) <= 1,5 x the upper limit nromale\n\n          -  Serum creatinine <140 \u00b5mol / L (or clearance> 60 mL / min)\n\n          -  Information and signed informed consent before inclusion in the study\n\n          -  Patient affiliated to a social security\n\n        Specific inclusion criteria for cohort 1:\n\n          -  grade I\n\n        Specific inclusion criteria for cohort 2:\n\n          -  grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of\n             the LDH)\n\n          -  grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the\n             LDH)\n\n          -  grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and\n             LDH < 2 times normal limit and/or supradiaphragmatic reach with pulmonary metastasis\n             and LDH < 2 times normal limit) either at initial diagnosis or relapse of a grade I\n             seminoma)\n\n          -  PET-TDM positive (pathological fixation on metastatic lesions)\n\n        Exclusion Criteria shared:\n\n          -  Patient infected by HIV, Hepatitis B or C\n\n          -  History, within 5 years, of cancer other than seminoma, except for treated skin\n             cancer (Basal Cell) .\n\n          -  visceral metastasis\n\n          -  cerebral metastasis\n\n          -  Any physical or mental condition incompatible with the treatment (to the investigator\n             discretion)\n\n          -  Uncontrolled or severe cardiovascular pathology\n\n          -  Uncontrolled or severe hepatic pathology\n\n          -  Persons deprived of liberty or under guardianship\n\n          -  Unable to undergo medical monitoring due to geographical, social or psychological\n             reasons"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "271", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887340", 
            "org_study_id": "2012-A01615-38", 
            "secondary_id": "2012/1884"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "- carboplatine: Dose (mg) = AUC x (GFR + 25)\nGFR : glom\u00e9rulaire filtration (ml/min)\nAUC : area under curve (mg/ml x min)", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "100 mg/m2 D1 to D5", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "20 mg/m2 de D1 to D5", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide phosphate", 
                "Cisplatin", 
                "Etoposide", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "contact": {
                "email": "yohann.loriot@gustaveroussy.fr", 
                "last_name": "Yohann LORIOT, MD", 
                "phone": "0142115276", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Gustave Roussy"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma", 
        "overall_contact": {
            "email": "yohann.loriot@gustaveroussy.fr", 
            "last_name": "Yohann LORIOT, MD", 
            "phone": "0142115276", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "emilie.lannoy@gustaveroussy.fr", 
            "last_name": "Emilie LANOY", 
            "phone": "0142114121", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Yohann LORIOT, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of patients without pathological fixation at the time of the inclusion PET-TDM (cohort 1) or at the time of the PET-TDM following two cycles of chemotherapy (Etoposiede+Cisplatine) (cohort 2) and getting a lighten protocol", 
            "measure": "Rate of patients without pathological fixation", 
            "safety_issue": "No", 
            "time_frame": "Assessed at the time of inclusion or after 2 cycles of chemotherapy, up to 21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887340"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Rate of patients without pathological fixation at the time of the inclusion PET-TDM (cohort 1) or at the time of the PET-TDM following two cycles of chemotherapy (Etoposiede+Cisplatine) (cohort 2)", 
                "measure": "Rate of patients without pathological fixation", 
                "safety_issue": "No", 
                "time_frame": "Assessed at the time of inclusion or after 2 cycles of chemotherapy, up to 21 days"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to 5 years"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}